CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02171 CARSGEN-B

Trading 10-28 13:16:52

11.290

+0.040

+0.36%

High11.470	Low10.970	Vol444.00K
Open10.970	D1 Closing11.250	Amplitude4.44%
Mkt Cap6.71B	Tradable Cap6.71B	Total Shares594.00M
T/O4.96M	T/O Rate0.07%	Tradable Shares594.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"CARSGEN-B","latestPrice":11.29,"timestamp":1793164591098,"preClose":11.25,"halted":0,"volume":444000,"delay":0,"changeRate":0.00355555555555548,"floatShares":594000000,"shares":594000000,"eps":-0.177264,"marketStatus":"Trading","change":0.04,"latestTime":"10-28 13:16:52","open":10.97,"high":11.47,"low":10.97,"amount":4963278,"amplitude":0.044444,"askPrice":11.3,"askSize":3500,"bidPrice":11.29,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.173,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1793175000000},"marketStatusCode":2,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":11.25,"openAndCloseTimeList":[[1793151000000,1793160000000],[1793163600000,1793174400000]],"volumeRatio":0.678603,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2678132446","title":"Results of CARsgen's Satri-Cel for Adjuvant Treatment for Gastric Cancer Presented at Esmo Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2678132446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678132446?lang=en_us&edition=fundamental","pubTime":"2026-10-26 08:30","pubTimestamp":1792974600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUAWDCN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1585","BK1587","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157533531","title":"CARsgen Announces Preliminary Phase Ib Data for Satri-cel Consolidation Therapy in Resected Gastric Cancer at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1157533531","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157533531?lang=en_us&edition=fundamental","pubTime":"2026-10-26 08:20","pubTimestamp":1792974036,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited (CARsgen) disclosed that preliminary results from its China-based Phase Ib study (CT041-CG4010, NCT06857786) of satricabtagene autoleucel (satri-cel, CT041) were...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105631088","title":"Carsgen-B (02171): Results from Kailimei® Study Presented at 2026 ESMO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1105631088","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105631088?lang=en_us&edition=fundamental","pubTime":"2026-10-26 08:18","pubTimestamp":1792973897,"startTime":"0","endTime":"0","summary":"According to an announcement from Carsgen-B (02171), preliminary results from a clinical trial (CT041-CG4010, NCT06857786) conducted in China evaluating Kailimei® (satri-cel injection, product code:...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1161","BK1587","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675238484","title":"CARsgen Doses First Patient in China Trial of T-Cell Therapy for Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2675238484","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675238484?lang=en_us&edition=fundamental","pubTime":"2026-10-13 10:15","pubTimestamp":1791857704,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics  dosed the first patient in a registrational Phase 1 trial in China of CT0596, an allogeneic CAR T-cell therapy targeting BCMA for relapsed or refractory multiple myeloma, according to a Tuesday Hong Kong bourse filing.Earlier investigator-initiated trials showed preliminary favorable tolerability and encouraging efficacy signals in patients with relapsed or refractory multiple myeloma and primary plasma cell leukemia, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1161","BK1587","02171","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143576658","title":"CARsgen-B: First Patient Dosed with Allogeneic BCMA CAR-T Candidate CT0596 in China Registrational Phase I Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1143576658","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143576658?lang=en_us&edition=fundamental","pubTime":"2026-10-13 08:21","pubTimestamp":1791850888,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited (CARsgen-B; 02171) announced the inaugural patient dosing of CT0596 in its registrational Phase I clinical trial in China. The study targets adults with relapsed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674450816","title":"Breakeven On The Horizon For CARsgen Therapeutics Holdings Limited (HKG:2171)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674450816","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674450816?lang=en_us&edition=fundamental","pubTime":"2026-10-11 10:05","pubTimestamp":1791684354,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited ( HKG:2171 ) is possibly approaching a major achievement in its business, so we...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/breakeven-on-the-horizon-for-carsgen-therapeutics-holdings-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/breakeven-on-the-horizon-for-carsgen-therapeutics-holdings-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02171","BK1161","BK4539","BK1585","BK1587","BK1574","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137766883","title":"CARsgen Therapeutics Reports Director Resignation and Audit Committee Shortfall Under HKEX Rule 3.21","url":"https://stock-news.laohu8.com/highlight/detail?id=1137766883","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137766883?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:42","pubTimestamp":1790775766,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited announced that Non-Executive Director Mr. Huaqing Guo resigned with effect from 30 September 2026 to focus on other business commitments. His departure also ends...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184326594","title":"Guo Huaqing Steps Down as Non-Executive Director of CARsgen-B (02171)","url":"https://stock-news.laohu8.com/highlight/detail?id=1184326594","media":"Stock News","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184326594?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:08","pubTimestamp":1790773704,"startTime":"0","endTime":"0","summary":"CARsgen-B (02171) has announced that Mr. Guo Huaqing has tendered his resignation as a non-executive director of the company.The resignation will take effect on September 30, 2026.The company stated...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1574","02171","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146102396","title":"CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B","url":"https://stock-news.laohu8.com/highlight/detail?id=1146102396","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146102396?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:10","pubTimestamp":1790640613,"startTime":"0","endTime":"0","summary":"According to an announcement by CARSGEN-B (02171), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1585","MDTX","02171","BMED","IBBJ","PSYK","BK1587","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671707265","title":"CARsgen Says First Patient Dosed in China Phase I Registrational Trial of Ct1190b CAR-T for R/R LBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2671707265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671707265?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640058,"startTime":"0","endTime":"0","summary":"CARsgen says first patient dosed in China Phase I registrational trial of CT1190B CAR-T for R/R LBCLCARsgen dosed the first patient in China in a registrational Phase I trial of CT1190B for relapsed o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4XW7vr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1161","BK1585","BK1574","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106932857","title":"CARsgen-B Posts 1H 2026 Revenue Growth, Narrower Loss After Top-up Placement and Satri-cel Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1106932857","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106932857?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:25","pubTimestamp":1789467950,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited (CARsgen-B) reported interim results for the six months ended 30 June 2026, showing continued commercial progress of its CAR-T portfolio and a strengthened cash...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CARsgen-B Posts 1H 2026 Revenue Growth, Narrower Loss After Top-up Placement and Satri-cel Approval","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128202984","title":"CARSGEN-B (02171) Climbs Nearly 3% in Morning Trade as FNC Lymphodepletion Regimen Receives Official Patent in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1128202984","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128202984?lang=en_us&edition=fundamental","pubTime":"2026-09-14 12:00","pubTimestamp":1789358424,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its shares rise nearly 3% before noon, last trading up 2.47% at HK$12.86 with a turnover of HK$16.44 million. The uptick follows the company's announcement on September 14 that...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","VXUS","02171","BK4588","KCAI","BK1585","BK4585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195415295","title":"HK Business Breakthrough Drives Nearly 5% Intraday Rally for CARSGEN-B","url":"https://stock-news.laohu8.com/highlight/detail?id=1195415295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195415295?lang=en_us&edition=fundamental","pubTime":"2026-09-11 10:50","pubTimestamp":1789095018,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its share price climb nearly 5% during intraday trading, building on optimistic market sentiment. As of the latest update, shares were up 1.84%, trading at HKD 12.70 with a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02171","BK1587","BK1585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431424","title":"CARsgen Therapeutics (SEHK:2171) Stock Carries Premium Valuation Despite Ongoing Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431424","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431424?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:27","pubTimestamp":1787142431,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings closed at HK$14.90 today after a choppy few months in which the stock has slipped about 15% over 90 days. Yet behind the weak chart, the latest half year numbers point to one issue that matters most for you as a shareholder. The balance sheet and valuation strain is now the key tension between short term sentiment and long term promise.\nRevenue for the first half of 2026 came in at ¥61.9 million, while the company still reported a net loss of ¥66.7 million. With...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-sehk2171-stock-carries-premium-valuatio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-sehk2171-stock-carries-premium-valuatio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","BK4007","BK4139","BK1585","LENZ","BK1574","BK4539","BK1161","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155552295","title":"CARSGEN-B Surges Nearly 5% Post-Earnings as Mid-Year Revenue Climbs 21.5% to RMB 61.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1155552295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155552295?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:20","pubTimestamp":1787106032,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its shares rally nearly 5% in Thursday morning trade following the release of its interim results. The stock was up 4.63% at HK$15.38 at the time of writing, with turnover...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1161","02171","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660241822","title":"Press Release: CARsgen Therapeutics Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660241822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660241822?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:15","pubTimestamp":1787098500,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results.Business Highlights-- Cash and cash equivalents were around RMB1,400 million as of June 30,2026. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,200 million. In light of operational factors, we expect to. -- During H1, 2026, CARsgen has received a total of 110 confirmed orders of. -- Satri-cel receives NMPA approval in June 2026 as world's first and only. CAR-T for solid tumors. Data of satri-cel as sequential therapy after 1L. treatment in patients with G/GEJA have been presented at the 2026 ASCO. -- Multiple allogeneic CAR T-cell products are under development based on. the proprietary THANK--u Plus platform. Among them, research results. for CT0596 in the treatment of R/R MM and PCL, as well as for CT1190B in. the treatment of R/R B--NHL, have been presented at the E","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU1674673428.USD","LU0203345920.USD","IE00B3PB1722.GBP","LU2328871848.SGD","CSCO","000963","SG9999001440.SGD","02171","LU0868494617.USD","LU1430594728.SGD","LU0942090050.USD","LU1032955483.USD","LU2237443465.HKD","BK1587","IYZ","LU2462157665.USD","LU2506952097.USD","R","LU0823417653.USD","BK4022","BK4230","BK4533","AIQ","LU1046421795.USD","BK1574","IE00B42XCP33.USD","LU2417539215.USD","BK4515","CAR","LU1929549753.HKD","CSCL","BK0187","LENZ","IE00BVYPNV92.GBP","SG9999001424.SGD","BK0209","IE00B1BXHZ80.USD","LU1221951129.SGD","LU2237443622.USD","BK4612","LU0950375773.USD","LU1599440770.SGD","TM","CSCS","CIBR","BK4534","PC","BK4560","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494978","title":"CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494978","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494978?lang=en_us&edition=fundamental","pubTime":"2026-08-19 02:24","pubTimestamp":1787077458,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1585","BK4007","BK1161","BK4139","BK1587","BK1574","BK4539","IND","02171","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142295338","title":"CARsgen Therapeutics posts narrower interim loss; revenue up 21.5% on BCMA CAR-T sales, cash boosted by HK$462 million placing","url":"https://stock-news.laohu8.com/highlight/detail?id=1142295338","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142295338?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:46","pubTimestamp":1787064361,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics (CARSGEN-B, 02171) released its unaudited results for the six months ended 30 June 2026. Financial highlights   • Revenue rose 21.5% year-on-year to RMB61.92 million, driven by...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CARsgen Therapeutics posts narrower interim loss; revenue up 21.5% on BCMA CAR-T sales, cash boosted by HK$462 million placing","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182420401","title":"CARsgen-B Posts Interim Results with 11.52% Narrower Loss Attributable to Owners","url":"https://stock-news.laohu8.com/highlight/detail?id=1182420401","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182420401?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:38","pubTimestamp":1787063895,"startTime":"0","endTime":"0","summary":"CARsgen-B (02171) has released its interim results for 2026, reporting revenue of approximately RMB 61.919 million, a year-on-year increase of 21.5%. The adjusted net loss came in at RMB 31.927...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1161","02171","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544493","title":"CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544493","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660544493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:28","pubTimestamp":1787063306,"startTime":"0","endTime":"0","summary":"CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 millionCARsgen posted revenue of RMB 62 million, up 21.58% year over year, driven mainly by zevor-cel sales vol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbGD37X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","LU2328871848.SGD","BK1587","BK0183","BK0187","BK0196","BK1585","02171","BK1574","BK1161","BK0132","BK0209","BK0175","000963","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.0672},{"period":"1month","weight":-0.1272},{"period":"3month","weight":-0.1667},{"period":"6month","weight":-0.4792},{"period":"1year","weight":-0.3296},{"period":"ytd","weight":-0.2424}],"compareEarnings":[{"period":"1week","weight":-0.0346},{"period":"1month","weight":-0.0599},{"period":"3month","weight":-0.1072},{"period":"6month","weight":-0.1061},{"period":"1year","weight":-0.1283},{"period":"ytd","weight":-0.101}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.015777},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.022715},{"month":8,"riseRate":0.5,"avgChangeRate":0.052678},{"month":9,"riseRate":0.333333,"avgChangeRate":0.020205},{"month":10,"riseRate":0.5,"avgChangeRate":0.002845},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"CARSGEN-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CARSGEN-B,02171,CARSGEN-B股票,CARSGEN-B股票老虎,CARSGEN-B股票老虎国际,CARSGEN-B行情,CARSGEN-B股票行情,CARSGEN-B股价,CARSGEN-B股市,CARSGEN-B股票价格,CARSGEN-B股票交易,CARSGEN-B股票购买,CARSGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}